301 related articles for article (PubMed ID: 30797052)
1. Cross-genotype AR3-specific neutralizing antibodies confer long-term protection in injecting drug users after HCV clearance.
Merat SJ; Bru C; van de Berg D; Molenkamp R; Tarr AW; Koekkoek S; Kootstra NA; Prins M; Ball JK; Bakker AQ; de Jong MD; Spits H; Beaumont T; Schinkel J
J Hepatol; 2019 Jul; 71(1):14-24. PubMed ID: 30797052
[TBL] [Abstract][Full Text] [Related]
2. Broadly Neutralizing Antibodies Targeting New Sites of Vulnerability in Hepatitis C Virus E1E2.
Colbert MD; Flyak AI; Ogega CO; Kinchen VJ; Massaccesi G; Hernandez M; Davidson E; Doranz BJ; Cox AL; Crowe JE; Bailey JR
J Virol; 2019 Jul; 93(14):. PubMed ID: 31068427
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis C virus Broadly Neutralizing Monoclonal Antibodies Isolated 25 Years after Spontaneous Clearance.
Merat SJ; Molenkamp R; Wagner K; Koekkoek SM; van de Berg D; Yasuda E; Böhne M; Claassen YB; Grady BP; Prins M; Bakker AQ; de Jong MD; Spits H; Schinkel J; Beaumont T
PLoS One; 2016; 11(10):e0165047. PubMed ID: 27776169
[TBL] [Abstract][Full Text] [Related]
4. Broad Anti-Hepatitis C Virus (HCV) Antibody Responses Are Associated with Improved Clinical Disease Parameters in Chronic HCV Infection.
Swann RE; Cowton VM; Robinson MW; Cole SJ; Barclay ST; Mills PR; Thomson EC; McLauchlan J; Patel AH
J Virol; 2016 May; 90(9):4530-4543. PubMed ID: 26912610
[TBL] [Abstract][Full Text] [Related]
5. Recombinant hepatitis C virus envelope glycoprotein vaccine elicits antibodies targeting multiple epitopes on the envelope glycoproteins associated with broad cross-neutralization.
Wong JA; Bhat R; Hockman D; Logan M; Chen C; Levin A; Frey SE; Belshe RB; Tyrrell DL; Law JL; Houghton M
J Virol; 2014 Dec; 88(24):14278-88. PubMed ID: 25275133
[TBL] [Abstract][Full Text] [Related]
6. Repertoire and Neutralizing Activity of Antibodies Against Hepatitis C Virus E2 Peptide in Patients With Spontaneous Resolution of Hepatitis C.
Olbrich A; Wardemann H; Böhm S; Rother K; Colpitts CC; Wrensch F; Baumert TF; Berg T; Benckert J
J Infect Dis; 2019 Aug; 220(7):1209-1218. PubMed ID: 31165162
[TBL] [Abstract][Full Text] [Related]
7. Broadly neutralizing antibodies from an individual that naturally cleared multiple hepatitis C virus infections uncover molecular determinants for E2 targeting and vaccine design.
Keck ZY; Pierce BG; Lau P; Lu J; Wang Y; Underwood A; Bull RA; Prentoe J; Velázquez-Moctezuma R; Walker MR; Luciani F; Guest JD; Fauvelle C; Baumert TF; Bukh J; Lloyd AR; Foung SKH
PLoS Pathog; 2019 May; 15(5):e1007772. PubMed ID: 31100098
[TBL] [Abstract][Full Text] [Related]
8. B cell immunodominance in primary hepatitis C virus infection.
Brasher NA; Eltahla AA; Underwood A; Boo I; Rizzetto S; Walker MR; Rodrigo C; Luciani F; Maher L; Drummer HE; Tedla N; Lloyd AR; Bull RA
J Hepatol; 2020 Apr; 72(4):670-679. PubMed ID: 31785346
[TBL] [Abstract][Full Text] [Related]
9. Multiplex flow cytometry-based assay to study the breadth of antibody responses against E1E2 glycoproteins of hepatitis C virus.
Merat SJ; van de Berg D; Bru C; Yasuda E; Breij E; Kootstra N; Prins M; Molenkamp R; Bakker AQ; de Jong MD; Spits H; Schinkel J; Beaumont T
J Immunol Methods; 2018 Mar; 454():15-26. PubMed ID: 28855105
[TBL] [Abstract][Full Text] [Related]
10. Role of the E2 Hypervariable Region (HVR1) in the Immunogenicity of a Recombinant Hepatitis C Virus Vaccine.
Law JLM; Logan M; Wong J; Kundu J; Hockman D; Landi A; Chen C; Crawford K; Wininger M; Johnson J; Mesa Prince C; Dudek E; Mehta N; Tyrrell DL; Houghton M
J Virol; 2018 Jun; 92(11):. PubMed ID: 29540595
[TBL] [Abstract][Full Text] [Related]
11. Altered Glycosylation Patterns Increase Immunogenicity of a Subunit Hepatitis C Virus Vaccine, Inducing Neutralizing Antibodies Which Confer Protection in Mice.
Li D; von Schaewen M; Wang X; Tao W; Zhang Y; Li L; Heller B; Hrebikova G; Deng Q; Ploss A; Zhong J; Huang Z
J Virol; 2016 Dec; 90(23):10486-10498. PubMed ID: 27630242
[TBL] [Abstract][Full Text] [Related]
12. Antibodies Targeting Novel Neutralizing Epitopes of Hepatitis C Virus Glycoprotein Preclude Genotype 2 Virus Infection.
Deng K; Liu R; Rao H; Jiang D; Wang J; Xie X; Wei L
PLoS One; 2015; 10(9):e0138756. PubMed ID: 26406225
[TBL] [Abstract][Full Text] [Related]
13. Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus.
Giang E; Dorner M; Prentoe JC; Dreux M; Evans MJ; Bukh J; Rice CM; Ploss A; Burton DR; Law M
Proc Natl Acad Sci U S A; 2012 Apr; 109(16):6205-10. PubMed ID: 22492964
[TBL] [Abstract][Full Text] [Related]
14. Native Folding of a Recombinant gpE1/gpE2 Heterodimer Vaccine Antigen from a Precursor Protein Fused with Fc IgG.
Logan M; Law J; Wong JAJ; Hockman D; Landi A; Chen C; Crawford K; Kundu J; Baldwin L; Johnson J; Dahiya A; LaChance G; Marcotrigiano J; Law M; Foung S; Tyrrell L; Houghton M
J Virol; 2017 Jan; 91(1):. PubMed ID: 27795422
[TBL] [Abstract][Full Text] [Related]
15. Novel adeno‑associated virus‑based genetic vaccines encoding hepatitis C virus E2 glycoprotein elicit humoral immune responses in mice.
Zhu F; Wang Y; Xu Z; Qu H; Zhang H; Niu L; Xue H; Jing D; He H
Mol Med Rep; 2019 Feb; 19(2):1016-1023. PubMed ID: 30569131
[TBL] [Abstract][Full Text] [Related]
16. Immunization with a synthetic consensus hepatitis C virus E2 glycoprotein ectodomain elicits virus-neutralizing antibodies.
Tarr AW; Backx M; Hamed MR; Urbanowicz RA; McClure CP; Brown RJP; Ball JK
Antiviral Res; 2018 Dec; 160():25-37. PubMed ID: 30217650
[TBL] [Abstract][Full Text] [Related]
17. Characterization of linear epitope specificity of antibodies potentially contributing to spontaneous clearance of hepatitis C virus.
Ahsan A; Dar S; Hassan F; Ghafoor F; Yousuf MH; Shahzad-Ul-Hussan S
PLoS One; 2021; 16(8):e0256816. PubMed ID: 34449828
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis C cross-genotype immunity and implications for vaccine development.
Islam N; Krajden M; Shoveller J; Gustafson P; Gilbert M; Wong J; Tyndall MW; Janjua NZ;
Sci Rep; 2017 Sep; 7(1):12326. PubMed ID: 28951612
[TBL] [Abstract][Full Text] [Related]
19. A Recombinant Hepatitis C Virus Genotype 1a E1/E2 Envelope Glycoprotein Vaccine Elicits Antibodies That Differentially Neutralize Closely Related 2a Strains through Interactions of the N-Terminal Hypervariable Region 1 of E2 with Scavenger Receptor B1.
Johnson J; Freedman H; Logan M; Wong JAJ; Hockman D; Chen C; He J; Beard MR; Eyre NS; Baumert TF; Tyrrell DL; Law JLM; Houghton M
J Virol; 2019 Nov; 93(22):. PubMed ID: 31462563
[TBL] [Abstract][Full Text] [Related]
20. Quantitative antibody responses to structural (Core) and nonstructural (NS3, NS4, and NS5) hepatitis C virus proteins among seroconverting injecting drug users: impact of epitope variation and relationship to detection of HCV RNA in blood.
Beld M; Penning M; van Putten M; Lukashov V; van den Hoek A; McMorrow M; Goudsmit J
Hepatology; 1999 Apr; 29(4):1288-98. PubMed ID: 10094977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
